{"meshTagsMajor":["Drug Discovery","Models, Molecular"],"meshTags":["Catalytic Domain","Cell Line, Tumor","Cell Proliferation","Drug Discovery","Humans","Inhibitory Concentration 50","Models, Molecular","Molecular Structure","Mutation","Protein Kinase Inhibitors","Receptor, Epidermal Growth Factor"],"meshMinor":["Catalytic Domain","Cell Line, Tumor","Cell Proliferation","Humans","Inhibitory Concentration 50","Molecular Structure","Mutation","Protein Kinase Inhibitors","Receptor, Epidermal Growth Factor"],"genes":["EGFR-T790M","L858R","EGFR-T790M","L858R","EGFR-T790M","L858R","wild-type EGFR","wild-type and mutant EGFR","EGFR","EGFR"],"organisms":["9606"],"publicationTypes":["Journal Article","Research Support, Non-U.S. Gov\u0027t"],"abstract":"Through a receptor-based and ligand-based combined virtual screening protocol, 21 novel compounds covering 15 scaffolds were identified as novel inhibitors for EGFR-T790M/L858R, among which, 12 of them were identified as selective inhibitors for EGFR-T790M/L858R to wild-type EGFR, and 5 of them exhibited \u0027dual-effective\u0027 to wild-type and mutant EGFR. Meanwhile, their antiproliferative effects toward EGFR high-expressing human lung cancer cell (A549), epidermoid carcinoma cell (A431), and the mutant EGFR-dependent cell (NCI-H1975) were also evaluated.","title":"Discovery of novel selective inhibitors for EGFR-T790M/L858R.","pubmedId":"22227214"}